Search the Newsreel

Autoliv Inc (ALV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Autoliv Inc (ALV), indicating its current valuation score is 7.87, ranking 44 out of 69 in the Automobiles & Auto Parts industry. The company's P/E ratio is noted at 12.82, which is significantly below its recent high …

ALV|Autoliv Inc|Price:124.670|Chg%:+0.560

Autoliv Inc. (ALV) is trading at 124.670 USD, experiencing a slight increase of 0.45%. The company's fundamentals are robust with high growth potential and a "fairly valued" classification within the Automobiles & Auto Parts industry. Analyst ratings are predominantly "Buy" with a target price …

Alvotech SA (ALVO) Cash Flow

This article provides a detailed look at Alvotech SA's (ALVO) cash flow statement, including operating, investing, and financing cash flow data presented quarterly and annually. It includes specific financial figures for these categories over several fiscal quarters, highlighting changes year-over-year. The article also features …

Valvoline Inc (VVV) Institutional Confidence

Valvoline Inc (VVV) has an institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion is 127.83%, an 11.19% increase quarter-over-quarter. ETHSX is the largest institutional shareholder with 2.64M shares, representing 2.12% of outstanding shares.

Palvella Therapeutics Inc (PVLA) Financial Health: Profitability & Balance Sheet Analysis

Palvella Therapeutics Inc (PVLA) has a robust financial status with a current financial score of 6.80, ranking 202 out of 386 in the Biotechnology & Medical Research industry, however, its operating efficiency is low. The article notes that relevant financial data regarding quality of …

Palvella Therapeutics Market Sentiment

This article provides an overview of market sentiment for Palvella Therapeutics (PVLA), including analyst consensus, short interest, options flow, and insider activity. Analysts currently have a "Buy" consensus with an average price target of $161, projecting a 15.0% upside. The short float is noted …

2 Cash-Producing Stocks to Target This Week and 1 We Turn Down

2 Cash-Producing Stocks to Target This Week and 1 We Turn Down A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cash flow is valuable, but it's not everything - …

Alvotech SA (ALVO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Alvotech SA (ALVO), listing both major shareholders and institutional holdings. It shows that Aztiq Pharma Partners SARL and Celtic Holdings SCA are the largest shareholders, alongside other institutional investors. The report also includes historical data on institutional …

Palvella Therapeutics Inc (PVLA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Palvella Therapeutics Inc (PVLA), listing its major shareholders and their respective proportions. It also provides institutional shareholding data over several quarters, showing the number of institutions, shares held, and proportional changes. Additionally, the article highlights recent shareholder …

Palvella Therapeutics Inc (PVLA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Palvella Therapeutics Inc (PVLA). It states that PVLA has not distributed any dividends in the past five years and lists stock split events, specifically an 80-to-1 merger on April 18, 2024. The company's current …

Palvella Therapeutics, Inc. $PVLA Stock Position Increased by First Light Asset Management LLC

ALV|Autoliv Inc|Price:117.490|Chg%:+2.290

This article provides a detailed financial overview of Autoliv Inc (ALV), including its stock performance, key financial indicators, and analyst ratings. It features comprehensive quarterly and annual data for revenue, EPS, net profit, margins, and balance sheet items like assets and liabilities. The report …

Autoliv, Inc. Revenue Breakdown – NYSE:ALV

This article provides a detailed revenue breakdown for Autoliv Inc (ALV) across its business segments and geographic regions. Autoliv's revenue is primarily driven by Airbag Products and Other (67.52%) and Seatbelt Products (32.48%). Regionally, the Americas contribute the largest share (32.18%), followed closely by …

ETFs Investing in Valvoline, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Valvoline, Inc. (VVV) stocks, providing key financial data for each. The data includes market value, weight of VVV in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, …

Autoliv Inc (ALV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Autoliv Inc (ALV) across its business segments and geographic regions. Autoliv's revenue is primarily driven by Airbag Products and Other (67.52%) and Seatbelt Products (32.48%). Regionally, the Americas contribute the largest share (32.18%), followed closely by …

Autoliv Inc. Revenue Breakdown – GETTEX:LIV

Autoliv Inc. (GETTEX:LIV) generated 9.21 billion EUR in revenue last year, with its Airbag, Steering Wheels segment contributing the most at 6.22 billion EUR. Europe was the largest regional contributor, accounting for 2.65 billion EUR of the company's revenue.

Autoliv Inc (ALV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividends and stock splits for Autoliv Inc (ALV). It lists several past and future dividend payments, including ex-dividend dates, record dates, and payment dates, with the gross cash dividend amounts. Over the last five years, Autoliv Inc …

A3LUCK Bond Risk Profile

This article provides an overview of the A3LUCK bond, specifically Autoliv, Inc. 3.625% 07-AUG-2029. It highlights the bond's risk assessment and mentions features like security level, inflation protection, and issuer rating to help investors evaluate its reliability. The content also notes access to exclusive …

Valvoline Inc (VVV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Valvoline Inc (VVV), highlighting its financial status with a focus on regional revenue distribution. As of the latest update, the company's revenue is predominantly from the United States, accounting for 96.89% of the total, with the international …

Alvotech Revenue Breakdown – NASDAQ:ALVO

Alvotech (NASDAQ: ALVO) generated $593.20 million USD in revenue last year, primarily from its Biosimilar Medicines segment, which accounted for $586.32 million USD. The company's revenue from this segment increased from $489.68 million USD in the previous year. Europe was the largest contributor to …

HSBC to sell Singapore life insurance arm to Allianz for $2.09bn

HSBC Holdings has agreed to sell its Singapore life and health (L&H) insurance business, HSBC Life (Singapore) (HSBC Life SG), to Germany's Allianz for S$2.7bn ($2.09bn). Under the deal, HSBC Insurance (Asia-Pacific) Holdings, an indirect wholly owned subsidiary of HSBC, will sell 100% of …

Enterprise value to revenue forward of Palvella Therapeutics, Inc. – FWB:PI6

This article provides a financial overview of Palvella Therapeutics, Inc. (FWB:PI6) on the Frankfurt Stock Exchange, specifically highlighting its enterprise value to revenue forward metric. It also lists various products, services, and community features offered by TradingView, the platform on which the information is …

Katherine Irene Fogertey Acquires 1,810 Restricted Stock Units at Valvoline Inc.

Katherine Irene Fogertey has acquired 1,810 restricted stock units at Valvoline Inc. These units convert to common stock on a one-for-one basis, aligning her interests with shareholders. The article notes that further details are behind a login or registration wall.

Valvoline Inc. CEO Lori Ann Flees Acquires Deferred Stock Units, Signaling Strong Leadership Commitment

Valvoline Inc. CEO Lori Ann Flees has acquired deferred stock units, a move that signals her strong commitment to the company's long-term performance and aligns her interests with shareholders. This transaction, which took place on July 23, 2026, is seen as a positive indicator …

Valvoline Inc. (NYSE: VVV) CEO defers salary into 25 deferred stock units

Valvoline Inc. CEO Lori Ann Flees acquired 25 deferred stock units on July 23, 2026, by deferring her salary into the company's 2016 Deferred Compensation Plan. Each unit represents a contingent right to one share of common stock, payable upon specific events such as …

Valvoline Inc. (NYSE: VVV) grants director 1,810 FY 2026 restricted stock units

Valvoline Inc. granted director Scott Mezvinsky 1,810 FY 2026 Restricted Stock Units on July 22, 2026, as an annual award under the company's 2026 Omnibus Incentive Plan. These units convert one-for-one into common stock and vest on the first anniversary of the grant date, …

Women's Centre Autoliv Tunisia Empowers Women Workers

The Women's Centre in Tunisia, in collaboration with IndustriALL and FGTHCC-UGTT, held a training day at Autoliv's Nador site for women workers. The event focused on combatting violence against women, preventing it, and providing legal and social support. It also aimed to raise awareness …

Valvoline Inc. (VVV) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Valvoline Inc. (VVV), including its current stock price, historical performance data, and key financial metrics. The article details the company's business in automotive preventive maintenance, its recent earnings, and analyst insights, all presented with various …

WASATCH ADVISORS LP Reduces Stake in Valvoline Inc

WASATCH ADVISORS LP significantly reduced its stake in Valvoline Inc by selling over 1.9 million shares, a 24.03% decrease, at an average price of $39.54. This transaction suggests a strategic portfolio adjustment. Valvoline Inc, despite having strong profitability, growth indicators, and being modestly undervalued, …

Valvoline adds two executives to board of directors By Investing.com

Valvoline Inc. has appointed Katherine Fogertey and Scott Mezvinsky to its board of directors, effective Tuesday. Fogertey, formerly CFO of Shake Shack, brings financial and operational transformation expertise, while Mezvinsky, CEO of KFC, adds leadership experience in scaling franchise networks across the globe. These …

Alvotech (ALVO) Q4 2024 Earnings Report - Results, Call & Slides

Alvotech (ALVO) reported its Q4 2024 earnings, missing EPS consensus at -$0.14 against an expected -$0.03, but significantly beating revenue expectations with $151.21M compared to $97.99M, marking a 183.21% YoY increase. The company's earnings call was held on March 26, 2025, and their next …

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

This article summarizes recent analyst ratings for three healthcare stocks: Palvella Therapeutics (PVLA), Neogen (NEOG), and ACADIA Pharmaceuticals (ACAD). Palvella Therapeutics received a "Strong Buy" consensus with a significant upside potential, primarily due to a reiterated Buy rating from TD Cowen. Neogen holds a …

ALV: Autoliv Inc. Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for Autoliv Inc. (ALV), including its current stock price, market capitalization, volume, 52-week high/low, PE ratio, and EPS. It also features a sentiment analysis indicating bearish sentiment and links to recent news articles related to corporate earnings. …

What Makes Valvoline (VVV) a New Strong Buy Stock

Investors might want to bet on Valvoline (VVV), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole …

H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated its Buy rating on Palvella Therapeutics (NASDAQ:PVLA) with a $270.00 price target, despite a recent 21% stock decline following an updated corporate presentation. The FDA recently declined Breakthrough Therapy Designation for cVM, but the firm believes this denial has limited …

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst